Parkinson's disease (PD) is a neurodegenerative disorder that primarily affects dopamine-producing neurons in the substantia nigra, a region of the brain. This article aims to provide a comprehensive understanding of the disease, its pathogenesis, clinical features, diagnosis, and management strategies.
The hallmark of PD is the progressive loss of dopamine-producing neurons, leading to a decrease in striatal dopamine levels. This imbalance disrupts normal brain function, resulting in the characteristic motor symptoms of PD: bradykinesia, resting tremor, rigidity, and postural instability. Non-motor symptoms such as cognitive impairment, depression, and autonomic dysfunction may also occur.
Diagnosis of PD is primarily clinical and based on the presence of cardinal motor symptoms. Neuroimaging techniques like DaTscan can support the diagnosis, but they are not routinely used due to their high cost and limited availability. There are no definitive biomarkers for PD, making early diagnosis challenging.
Management of PD involves a multidisciplinary approach. Pharmacological treatment primarily aims to replace or mimic dopamine, with Levodopa being the most effective drug. Deep Brain Stimulation (DBS) is a surgical option for patients with advanced PD or those who do not respond to medication. Non-pharmacological interventions, including physiotherapy and occupational therapy, are also crucial in managing PD symptoms and improving quality of life.
Research is ongoing to develop disease-modifying therapies that can slow or halt the progression of PD. Genetic and environmental risk factors are being explored to understand their role in PD pathogenesis and to identify potential therapeutic targets.
Understanding Parkinson's disease requires a comprehensive approach, incorporating knowledge of its pathogenesis, clinical features, diagnostic challenges, and management strategies. As healthcare professionals, staying updated on the latest research and advancements can enable us to provide optimal care to our patients.
1.
"Unusual" Cancers Following Pandemic; Triumph in TNBC; Clinical Trial Interrupted by Shortage.
2.
Recently released national data on drug use and abuse among Americans.
3.
Despite Medicare Coverage, Cancer Genomic Testing Still Low
4.
Ketamine plus psychotherapy for "excellent" PTSD
5.
Psychedelic Therapy Tied to Reduced Depression, Anxiety.
1.
Personalized Tumor Ecological Landscapes in Oncology
2.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
3.
Preserving Social Identity During Cancer Survivorship
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Regenerative Models of Tumor Microenvironments: Clinical Relevance and Emerging Insights
1.
International Conference on Cancer Nursing and Rehabilitation Strategies
2.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
3.
International Conference on Innovations in Critical Care for Oncology and Cardiology
4.
International Symposium on Oncology, Cardiology and Critical Care Innovations
5.
International Conference on Cancer Nursing and Hematology Support
1.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
4.
From Guidelines to Practice: Hematology
5.
Breast Cancer Awareness and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation